Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly and Co. has begun selling its blockbuster weight-loss and diabetes drug Mounjaro in India, pipping rivals in a ...

Eli Lilly's stock is undervalued; defensive healthcare stocks shine amid uncertainty, and Eli Lilly drives growth. Click here ...

Eli Lilly s Pleasant Prairie facility expansion gets final approval, paving the way for a 3 billion Kenosha County investment ...

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

Eli Lilly plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S. The drugmaker, which had committed to $23 billion in domestic investments from 2020 ...

Eli Lilly lowered the price of two dosage levels of its weight-loss drug Zepbound for patients paying out of pocket. The company also launched new 7.5-mg and 10-mg single-use vials, which cost $ ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).